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Age-Related Differences in Susceptibility to Carcinogenesis.
II. Approaches for Application and Uncertainty Analyses for
Individual Genetically Acting Carcinogens
Dale Hattis,1 Robert Goble,1 and Margaret Chu 2
1George Perkins Marsh Institute, Clark University, Worcester, Massachusetts, USA; 2Office of Research and Development,
U.S. Environmental Protection Agency, Washington, DC, USA

In an earlier report we developed a quantitative likelihood-based analysis of the differences in
sensitivity of rodents to mutagenic carcinogens across three life stages (fetal, birth to weaning, and
weaning to 60 days) relative to exposures in adult life. Here we draw implications for assessing
human risks for full lifetime exposures, taking into account three types of uncertainties in making
projections from the rodent data: uncertainty in the central estimates of the life-stage–specific sensitivity factors estimated earlier, uncertainty from chemical-to-chemical differences in lifestage–specific sensitivities for carcinogenesis, and uncertainty in the mapping of rodent life stages
to human ages/exposure periods. Among the uncertainties analyzed, the mapping of rodent life
stages to human ages/exposure periods is most important quantitatively (a range of several-fold in
estimates of the duration of the human equivalent of the highest sensitivity “birth to weaning”
period in rodents). The combined effects of these uncertainties are estimated with Monte Carlo
analyses. Overall, the estimated population arithmetic mean risk from lifetime exposures at a constant milligrams per kilogram body weight level to a generic mutagenic carcinogen is about
2.8-fold larger than expected from adult-only exposure with 5–95% confidence limits of 1.5to 6-fold. The mean estimates for the 0- to 2-year and 2- to 15-year periods are about 35–55%
larger than the 10- and 3-fold sensitivity factor adjustments recently proposed by the U.S.
Environmental Protection Agency. The present results are based on data for only nine chemicals,
including five mutagens. Risk inferences will be altered as data become available for other chemicals. Key words: carcinogenesis, fetal, mutagenic chemicals, risk assessment, susceptibility, uncertainties. Environ Health Perspect 113:509–516 (2005). doi:10.1289/ehp.7564 available via
http://dx.doi.org/ [Online 10 January 2005]

Both the Safe Drinking Water Act (SDWA)
Amendments (1996) and the Food Quality
Protection Act (FQPA 1996) direct U.S.
Environmental Protection Agency (EPA) to
conduct studies to identify and characterize
health risks for groups that may be at greater
risk than the general population. For noncancer health effects, the FQPA (but not the
SDWA) mandates the use of a default additional 10-fold safety factor (10×) for protection
of children from noncancer effects unless specific data are available to indicate that this extra
protection is not needed. For carcinogenic
risks, as part of its revision of cancer risk assessment guidelines, the U.S. EPA has assembled
and analyzed animal cancer bioassay data for
exposures to mutagenic and putatively nonmutagenic chemicals over different periods of life.
On the basis of this analysis, the U.S. EPA
proposed a 10-fold upward adjustment in the
cancer potency for exposures to mutagenic carcinogens from birth to 2 years of age and a
3-fold adjustment for exposures between 3 and
15 years of age (U.S. EPA 2003).
In a previous report (Hattis et al. 2004), we
offered an improved analysis of the available
cancer bioassay data, using likelihood methods
to avoid excluding cases where no tumors were
observed in either adult or other groups and
providing for quantitative estimation of confidence limits for the data as a whole, and
Environmental Health Perspectives

selected subsets of the data. We expressed
dosage for animals of different weights on a
metabolically consistent basis (either concentration in air or food, or per unit body weight to
the three-quarters power). Finally, we used a
system of dummy variables to represent exposures during fetal, preweaning, and weaning
to 60-day postnatal periods—yielding separate estimates of relative sensitivity per day of
dosing in these intervals.
Briefly, the central estimate results of that
analysis indicated a 5- to 60-fold increased
carcinogenic sensitivity in the birth to weaning period per dose/(body weight3/4-day) for
mutagenic carcinogens, and a somewhat
smaller increase—centered about 5-fold—for
radiation carcinogenesis per Gray (100 rads).
Effects were greater in males than in females,
partly because of considerable differences in
the carcinogenic responsiveness of the liver
in males. There was a similar increased sensitivity in the fetal period for direct-acting
nitrosoureas, but no such increased fetal sensitivity was detected for carcinogens requiring
metabolic activation.
This present article is a follow-up to that
earlier work (Hattis et al. 2004) showing
how the previous results might be applied to
distributional risk analyses of specific mutagenic carcinogens. Doing this requires analyses of three particular sources of uncertainty:
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a) uncertainty in the central estimates of the
life-stage–specific sensitivity factors estimated
earlier, b) uncertainty from chemical-tochemical differences in life-stage–specific sensitivities for carcinogenesis, and c) uncertainty
in the mapping of rodent life stages to human
ages/exposure periods. The implications of
these three component uncertainties are
assessed in Monte Carlo simulations.
Methodology and results from assessing
each source of uncertainty separately are covered in the next three subsections. This is followed by a discussion of methodology and
results from the Monte Carlo simulations of
the combined effects. To convey our methods
and results as transparently as possible, and
allow others to extend the analyses, the underlying distributional input data and the Excel
Monte Carlo simulation models for each sex
are available via our website (Hattis 2004).
The results provide guidance on a) implications for human risk assessment for full lifetime exposures relative to adult-only exposures,
with comparisons with the human relative
susceptibility assumptions in the U.S. EPA
(2003) proposal and b) implications for
research priorities to reduce uncertainties.

Uncertainties in
Central Estimates of
Life-Stage–Specific Sensitivity
to Carcinogenesis for
Mutagenic Agents
Table 1 and Figures 1 and 2 show the results
of our prior analyses (Hattis et al. 2004) of the
overall central tendency differences between
exposures during various life stages and similar
Address correspondence to D. Hattis, George Perkins
Marsh Institute, Clark University, 950 Main St.,
Worcester, MA 01610 USA. Telephone: (617) 2832521. Fax: (508) 751-4600. E-mail: dhattis@aol.com
This manuscript has benefited greatly from review
comments by P. White and J. Vandenberg of the
EPA. We are also grateful to G. Ginsberg of the
Connecticut Department of Public Health for very
helpful inputs in preparation of the final manuscript.
This research is supported by a cooperative agreement with the U.S. Environmental Protection
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exposure (per unit body weight3/4 or per unit
concentration in external air or water or food)
per day during adulthood (> 60 days of age in
rodents). There are appreciable differences
between the estimated life-stage–specific increments in relative risk for the two sexes; therefore, all the analyses in this article are done
separately for males and females.
The origins of the sex difference are not
known; however, we note that there are conspicuous differences between male and female
rodents in the levels of cytochrome P450
(CYP) enzymes that are responsible for metabolic activation of several small-molecularweight mutagenic carcinogens. For example,
Chanas et al. (2003) have recently observed a
greater than 5-fold difference in CYP2E1 levels in male than in female adult mice, and
associated this with an enhanced male sensitivity to the toxicity of acrylonitrile. Early-life
differences in expression of specific CYPs have
been associated with sex differences in the frequency of growth hormone pulses observed in

the plasma of rodents (Pampori and Shapiro
1994; Pampori et al. 2001; Shapiro et al.
1995). Sex differences are also apparent in the
induction of some DNA repair enzymes
in vivo in rodent liver. For example, Chan
et al. (1992) observed over a 17-fold induction of O6-methyl-guanine methyl transferase
activity in the livers of female SpragueDawley rats after a high-dose (15 Gy) gamma
radiation exposure; this is compared with a
much smaller 3.5-fold induction in the livers
of male rats. Similar sex-related differences
were not observed in other organs. We are
not aware of direct comparisons of the induction of such DNA repair functions between
infant/juvenile and adult animals.
Figures 1 and 2 show log-normal probability plots (Hattis and Burmaster 1994) of the
statistical uncertainty distributions for the life
stage/adult sensitivity ratios for the male and
female combined discrete and continuous dosing data for mutagenic carcinogens. In this
type of plot, correspondence of the points to

Table 1. Comparative results for male versus female animals for mutagenic chemicals: analysis of combined data from continuous and discrete dosing experiments (nine compounds, 153 tumor incidence
observations).
Maximum likelihood estimate of cancer
inductions per dose/(body weight3/4-day)
relative to comparably dosed adults

Period
Male animals
Fetal
Birth to weaning
Weaning to 60 days
Female animals
Fetal
Birth to weaning
Weaning to 60 days

5–95%
confidence limits

25
57
5.0

Arithmetic
mean

15.6–42
38–90
3.1–8.6

1.77
4.4
0.82

27
59
5.3

1.05–2.9
3.3–6.0
0.50–1.29

1.83
4.5
0.85

Data from Hattis et al. (2004).
y = 0.646 + 0.0785x
y = 0.246 + 0.134x
y = –0.0880 + 0.124x

R 2 = 1.000
R 2 = 1.000
R 2 = 0.999

Male log (birth-wean/adult)
Male log (fetal/adult)
Male log (wean-60 day/adult)

1.0

0.8

0.6

0.4 3× greater than adult risk
95% upper
confidence limits
0.2

0.0
No difference from
adult risk
–0.2

–0.4
–2
–1
95% lower
confidence limits

0

1

2

Z-score

Figure 1. Females: log-normal plots of likelihoodbased uncertainty distributions in rates of cancer
transformations per daily dose for various life stages
for mutagenic chemicals (relative to comparable
exposures of adults) for combined discrete and continuous dosing experiments. BW, body weight.

510

y = 1.76 + 0.113x
y = 1.41 + 0.132x
y = 0.705 + 0.133x

R 2 = 0.999
R 2 = 1.000
R 2 = 0.999

2.2

Male log (period/adult risk/daily dose/BW3/4)

Female log (period/adult risk/daily dose/BW3/4)

Female log (birth-wean/adult)
Female log (fetal/adult)
Female log (wean-60 day/adult)

2.0
1.8
1.6
3× greater than adult risk
1.4
95% upper
confidence limits

1.2
10× greater than adult risk

1.0
0.8
0.6

95% lower
confidence limits

0.4
–2

–1

0

1

2

Z-score

Figure 2. Males: log-normal plots of likelihood-based
uncertainty distributions in rates of cancer transformations per daily dose for various life stages for
mutagenic chemicals (relative to comparable exposures of adults) for combined discrete and continuous dosing experiments. BW, body weight.
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the fitted line is an indicator of the fit of a lognormal distribution to the statistical uncertainties in central estimate life stage/adult
sensitivity ratios. (The Z-score that makes up
the x-axis is the number of SEs above or below
the median of the normal distribution of
log10-transformed values). Figures 1 and 2
show that the uncertainty distributions from
the overall fits to the data are well described by
fitted log-normal distributions. We stress that
these plots are of confidence limits on the
aggregate geometric mean results for all chemicals in the covered groups.

Departures from
Life-Stage–Specific Model Fits
from the Central Estimates for
Individual Chemicals
A risk assessor or risk manager considering
the risks of exposure to a particular carcinogen faces more uncertainty than the simple
statistical confidence limits on the aggregate
fit of all the data quantified in the preceding
section. There is also the chance that the particular chemical under study differs in its relative life-stage–specific/adult sensitivity ratios
from the geometric mean of other chemicals
in the group providing observational data.
To give assessors and managers a preliminary set of estimates of chemical-to-chemical
differences, Table 2 shows an analysis of the
subset of the life-stage–specific carcinogenesis
data where groups of animals received exposure that was confined to a single life stage
(i.e., fetal, birth to weaning, or weaning to
60-day periods). Other data points contributing to the fits in Table 1 had exposures that
extended across various life stages, were for
adults only, or were unexposed controls. At
the bottom of the table are standard deviations of the common logarithms (using a base
of 10) of the departures of the chemicalspecific observations from the overall model
predictions. In the later Monte Carlo simulations, the antilog of this factor will be used as
the geometric standard deviation of a lognormally distributed multiplier for the lifestage–specific risks with a geometric mean
of 1. Figures 3 and 4 show that, although the
data are sparse, log-normal distributions are
generally reasonable descriptions of these
data.
The limited data for the fetal life stage also
suggest greater chemical-to-chemical differences than are present for the birth to weaning and weaning to 60-day exposure periods
(Table 2). Observations in the previous report
indicated that there were substantial differences
between direct-acting chemicals (nitrosoureas)
and chemicals requiring metabolic activation
in the extent of elevation of fetal-stage carcinogenesis sensitivity over the sensitivity to exposures during adulthood.
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A U.S. EPA committee (Brennan et al. 2003)
previously defined a series of human age
groups based on behavioral and physiologic
milestones likely to predict changes in exposure rates (Table 3). Unfortunately, it is not
clear how these proposed divisions relate to
the fetal, birth to weaning, and weaning to
60-day periods used in our previous analysis
of excess risks from rodent early-life exposures
to mutagenic carcinogens. Ideally, a theory
for interspecies mapping of differences in the
timing of enhanced susceptibility for carcinogenesis should be based on an understanding
of the carcinogenic process, and how it is
affected by age.
Considerable past work has emphasized
the potential for age-related differences in
long-term risks from carcinogenic exposures
that could result from early- versus late-life
exposure to carcinogens that tend to cause
mutations at a single stage that is either early
or late in the multistage molecular pathologic
Environmental Health Perspectives

Age-related differences in carcinogenesis

Armitage-Doll models in which different stage
transitions are enhanced by a carcinogenic
exposure.
Recent analyses of atomic bomb survivor
data have tended to de-emphasize this type of
mechanistic consideration. Analyses by Pierce
and Mendelsohn (1999) suggest that those
data are most compatible with a model in
which radiation enhances all stages of classical
Armitage-Doll processes (model III in Figure 5).
If this is correct, although excess relative risks

Table 2. Log(geometric mean) departures of age-related changes in susceptibility to carcinogenesis for
individual mutagenic carcinogens from model “predictions”—combining all available cancer sites for
each agent.a

Chemical

Log (observed/model predicted)
cancer transformations/animal relative to adults
Birth to weaning
Weaning to 60 days

Fetal

Male animals
Benzidine
Benzo[a]pyrene
Deithylnitrosamine
DMBA
Ethylnitrosourea
N-Nitroso-N-methylurea
Safrole
Urethane
SD
Female animals
Benzidine
Benzo[a]pyrene
Diethylnitrosamine
DMBA
Ethylnitrosourea
N-Nitroso-N-methylurea
Safrole
SD

0.004
ND
–0.961
ND
0.103
ND
–0.486
ND
0.490

0.163
0.017
–0.045
–0.108
–0.135
–0.257
0.084
0.008
0.132

–0.367
–0.045
0.132
–0.166
0.423
0.142
–0.236
–0.023
0.249

–0.104
ND
–1.086
ND
0.416
ND
ND
0.763

–0.111
0.037
–0.025
–0.087
0.006
–0.184
–0.720
0.269

ND
0.098
–0.172
–0.038
–0.142
0.038
ND
0.115

Abbreviations: DMBA, dimethylbenz[a]anthracene; ND, no data.
aData for only eight chemicals are shown, rather than the nine listed in Table 1, because for one chemical (vinyl chloride)
there were no experimental groups where dosing was confined entirely to one of the three pre-adult periods represented
here. Data combining exposures across periods and adulthood could contribute to the analysis for Table 1 because of the
use of the dummy-variable analysis methodology described in Hattis et al. (2004).
Male fetal/adult log (obs/pred)
Male birth-wean log (obs/pred)
Male wean-60 day log (obs/pred)

y = –0.335 + 0.530x
y = –0.034 + 0.141x
y = –0.017 + 0.264x

R 2 = 0.929
R 2 = 0.986
R 2 = 0.971

Female fetal/adult log (obs/pred)
y = –0.258 + 0.864x R 2 = 0.969
Female birth-wean log (obs/pred)
y = –0.112 + 0.255x R 2 = 0.781
Female wean-60 day log (obs/pred) y = –0.043 + 0.124x R 2 = 0.960
1.0

1.0
0.8

Female log (observed/model predicted
cancer sensitivity relative to adults)

Mapping Rodent Life Stages
to Human Periods:
Implications for Uncertainties
in Projections of Expected
Risks for Lifetime Exposures
to Mutagenic Carcinogens

sequence of genetic changes (Brown and Hoel
1986; Day and Brown 1980; Whittemore
1977). In general, carcinogenic risks will tend
to be greater for early-life exposure to a carcinogen that causes relevant early-stage transitions but will tend to be greater for late-life
exposure to a carcinogen that causes relevant
late-stage transitions. For example, Figure 5
shows the effects of age at exposure on
absolute excess risks against a 10% lifetime
background cancer for classical five-stage

Male log (observed/model predicted
cancer sensitivity relative to adults)

The approach represented here is not the
only possible way in which chemical-tochemical differences might have been analyzed. In some ways a better approach might
have been to estimate all of the coefficients
and uncertainties shown in Table 1 separately
for each chemical and sex. Had that been possible, we could have preserved for the Monte
Carlo simulations whatever dependencies
there might have been in the data between
life-stage–specific risk increments for individual chemicals. Unfortunately, this would have
required estimates of five different parameters
per sex per chemical per tumor site (the background rate of tumors, the tumor risk for
adult-only exposure, and the relative multiplicative increment of tumor risk for each of
the three life stages). After attempting this for
a few chemicals, we concluded that few if any
of the chemicals and tumor sites for which we
had information had rich enough data sets to
support robust estimation of the required five
independent parameters.
As an alternative, to check for dependencies we did simple pairwise correlation analyses
of the data in Table 2 for different life stages.
Of the six possible pairwise correlations, we
found only one that was marginally statistically
significant at p < 0.05—a finding that could
easily be the result of chance fluctuations and
multiple comparisons. We therefore elected
not to incorporate this possible dependency
into our Monte Carlo simulation analysis of
uncertainties in overall life stage–specific risks.

|

0.6
0.4
0.2
0.0
–0.2
–0.4
–0.6
–0.8
–1.0
–2

–1

0

1

2

Z-score

Figure 3. Males: probability plots of the individual
chemical geometric mean ratios of observed/geometric mean model predicted excess cancer transformations over control tumor rate/(dose/kg body
weight3/4) for treatment in various life stages relative
to adults.
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0.5

0.0

–0.5

–1.0

–1.5
–2

–1

0

1

2

Z-score

Figure 4. Females: probability plots of the individual
chemical geometric mean ratios of observed/geometric mean model predicted excess cancer transformations over control tumor rate/(dose/kg body
weight3/4) for treatment in various life stages relative
to adults.
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are much greater for early-life exposures in the
first decades after exposure, eventual lifetime
absolute risks per dose (the types of estimates
made by the U.S. EPA (1999) in its typical
slope factor assessments) are expected to be
much less influenced by age at exposure.
The most recent empirical excess absolute
risk descriptions from the atomic bomb survivor data (Preston et al. 2003) appear to
project lifetime absolute risks that are only
about twice as large for exposure before
15 years of age than for exposure between
15 and 60 years of age. It is not clear, however, that these data have been analyzed for
very fine breakdowns of early-life human
exposures (i.e., finer than 10-year age periods,
such as 0–9 years); 90% of the people in
the atomic bomb survivor group who were
exposed as 0- to 9-year-olds are still alive, so it
is likely that much more extensive examination of the eventual cancer mortality experience of the youngest exposed people will be
possible in the next few decades.
One plausible factor that may be contributing to life-stage–specific differences in
risks of carcinogenic transformation per unit
dose is a difference in cell replication rates for
relevant stem cells. During early life stages,
it is likely that these cells reproduce more
quickly to support the generation of additional
Table 3. Age groupings recommended by the U.S.
EPA for early-life exposure analyses.
Age groups < 1 yeara

Age groups ≥ 1 year

Birth to < 1 month
1 to < 3 months
3 to < 6 months
6 to < 12 months

1 to < 2 years
2 to < 3 years
3 to < 6 years
6 to < 11 years
11 to < 16 years
16 to < 18 years
18 to < 21 years to
be considered on a
case-by-case basis

aFor

evaluating exposure or potential dose but not internal
dose, it may be acceptable to combine some of these groups
(e.g., the first three groups could be combined to encompass
“birth to < 6 months”). Data from Brennan et al. (2003).
I
II
III
X IV

Absolute risk

12.00
10.00
8.00
6.00

X

4.00
2.00

X

X

0.00
0.00 10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00

Age at exposure (% life)

Figure 5. Effects of age at exposure on risks over
background for classical Armitage-Doll five-stage
multistage models in which the carcinogen
enhances different transitions over a background
lifetime risk of 10%: I, enhancement of the first
stage only; II, enhancement of the fourth stage
only; III, equal enhancement of all stages (Pierce
and Mendelsohn 1999); IV, smoking-radon analogy
two-thirds enhancement of stage I and one-third
enhancement of stage 4.
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cells at all stages of differentiation that are
required to make up the growing organism.
Because of more rapid reproduction of such
stem cells, there is likely to be less time to
accomplish DNA repair before copying and
the fixation of newly generated DNA lesions
into permanent point mutations and larger
chromosomal changes. Therefore, it is natural
to attempt to make some estimates of equivalent times in different species that are related
to some measures of growth in those species.
All measures of growth, of course, are not
equally likely to be accurate reflections of the
kind of stem cell replication that is likely to
lead to increases in vulnerability to carcinogenesis. Figures 6 and 7 contrast two measures
of growth—body weight versus height—that
are available for a large representative sample
of U.S. humans [from the Third National
Health and Nutrition Examination Survey
(NHANES III); National Center for Health
Statistics 1996]. Although growth in height
for average people ceases fairly abruptly at
15 or 16 years of age (depending on sex), average weights of U.S. humans continue to
increase well into middle age. Rats apparently
show a similar pattern of continual increase
in weight well into adulthood in standard
National Toxicology Program bioassay studies
(NTP 1999). Unfortunately, we were not able
to locate measurements of linear growth in
rodents that might provide more sharply
defined points of comparison for the data in
Figure 6. We were, however, able to obtain
data sets for body weight covering the postnatal (and in some cases prenatal) developmental periods (Figures 8 and 9).
Failing comparable measurements of linear
growth, we elected to anchor our weightrelated estimates of relative age to another type
of developmental milestone that occurs near
the age where “adulthood” is generally
defined—sexual maturity. Table 4 gives data
from a recent report (Kilborn et al. 2002)

describing times of the onset of sexual maturity
in different species. Using these developmental
anchor points, Tables 5 and 6 show the fraction of sexual maturity body weights achieved
at the borders between the various rodent
exposure periods used in the prior analysis, and
the ages at which average humans of each sex
achieve the same fractions of sexual-maturity
body weights. The human ages corresponding
to rodent weaning (assumed to be 21 postnatal
days in both mice and rats) show a large variation between projections from mouse versus rat
data, and within each rodent species between
males and females. This necessarily leads to
substantial uncertainties in alternative estimates
of the amount of human time that would correspond to the birth to weaning period in particular (Table 7). The length of this interval is
critical for the analysis here because the birth to
weaning period shows the greatest increase in
relative risk per dose per day of exposure
(Table 1), and the implications for lifetime
relative risk depend directly on how large a
part of the life span is covered by the “birth
to weaning” risk elevation per unit daily
dose/body weight3/4.
It is a substantial challenge to fairly represent
this uncertainty in a Monte Carlo analysis.
Some other analysts, faced with two estimates of
an uncertain quantity, have chosen to represent
the uncertainty with uniform distributions with
limits defined by the two points. Our view is
that this generally understates the associated
uncertainty because there can be no assurance
that the two available estimates happen to represent the absolute lowest and highest possible
values for the uncertain parameter. We believe
that sharp limits on uncertainty distributions
should be set only where there is good reason to
believe that values outside the limits are impossible (Hattis and Burmaster 1994). For the present case, we find it hard to believe that the
human equivalent of the total period from birth
through 60 days in rodents could be more than

180
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Figure 6. Population-weighted differences in mean
height (ht) for NHANES III subjects of different
ages (2–90 years).
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Figure 7. Population-weighted differences in
log(mean weight in kg) for NHANES III subjects of
different ages (2–90 years).
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about 15 years in females or 16 years in males—
corresponding to the average cessation of vertical growth seen in the NHANES III data
(Figure 6). We therefore chose to define lognormal uncertainty distributions as shown in
Table 7 for human equivalents of the various
rodent exposure periods, subject only to the limitation that within any Monte Carlo trial, the
total birth to weaning plus weaning to 60-day
equivalents could not exceed these sex-dependent limits. In cases where these limits were
exceeded on individual trials, both the component periods were reduced proportionately to
values that would add up to the prescribed limits. This introduced a negative dependency
between possible values for the birth to weaning
and weaning to 60-day periods.

Monte Carlo Simulation
Modeling of the Uncertainties
in Full-Life Exposures to a
Generic Mutagenic Carcinogen

subject to the 15- and 16-year limitations
described above.
The period-specific increments to lifetime
risk (relative to comparable adult period exposure, defined as 1) were then calculated as the
product of these three terms normalized to
the calculated duration of the adult period for
that trial. (The length of the adult period varied from trial to trial as the difference between
70 years and the sum of the human-equivalent birth to weaning and weaning to 60-day
periods.) The model spreadsheets available on
the website (Hattis 2004) should be consulted
for further methodologic details.
The uncertainty distributions for the sexspecific and life-stage–specific contributions to
expected lifetime risk are given in Table 8.

Using the Microsoft Excel rand( ) and normsinv( ) commands, (Microsoft Excel X for
Mac, Microsoft Corp., Redmond, WA) each
simulation trial drew random values for a
particular sex for the central estimate of the
risk/dose multiplier for each of the three periods relative to adults (see Figures 1 and 2 for
log-normal parameters), the chemical-tochemical relative risk multiplier [geometric
mean of 1 and log(geometric standard deviations) in Table 2], and the length of the
human equivalents of the three periods,

Table 5. Mice: inferences of corresponding human ages from weight-based comparisons relative to the
times of sexual maturity.

3.5
Male
Female
3.0

Time/event
Male mouse
Begin fetal dosing (GD12)
Birth (GD20)
Weaning (PND21)
Adult (PND60)
Female mouse
Begin fetal dosing (GD12)
Birth (GD20)
Weaning (PND21)
Adult (PND60)

2.5

Rat log (g BW)

Age-related differences in carcinogenesis

2.0

1.5

1.0

Fraction of
mouse weight at
sexual maturity

Source of human
weight data

Corresponding
human age

Unit of
human age

6.4 × 10–4
0.048
0.354
1.163

Potter and Craig 1975
Potter and Craig 1975
NHANES III
NHANES III

93
35
3.16
12.8

Gestation days
Gestation weeks
Postnatal years
Postnatal years

1.8 × 10–3
0.092
0.677
1.435

Potter and Craig 1975
Sunderman and Boerner 1949
NHANES III
NHANES III

112
14
7.40
15.1

Gestation days
Postnatal days
Postnatal years
Postnatal years

Abbreviations: GD, gestation day; PND, postnatal day.
0.5
0

20

40

60

80

100

Age (days)

Figure 8. Postnatal growth of Sprague-Dawley rats,
based on data compiled for the U.S. EPA. Data from
Gentry et al. (2003). BW, body weight.

Time/event
Male rat
Begin fetal dosing (GD12)
Birth (GD22)
Weaning (PND21)
Adult (PND60)
Female rat
Begin fetal dosing (GD12)
Birth (GD22)
Weaning (PND21)
Adult (PND60)

2.0
Male
Female

Mouse log (g BW)

Table 6. Rats: inferences of corresponding human ages from weight-based comparisons relative to the
times of sexual maturity.

1.5

1.0

0.5

Fraction of
mouse weight at
sexual maturity

Source of human
weight data

Corresponding
human age

Unit of
human age

6.3 × 10–5
0.023
0.195
1.035

Potter and Craig 1975
Potter and Craig 1975
NHANES III
NHANES III

66
28
0.44
11.7

Gestation days
Gestation weeks
Postnatal years
Postnatal years

6.3 × 10–5
0.029
0.250
1.025

Potter and Craig 1975
Potter and Craig 1975
NHANES III
NHANES III

66
30
0.90
10.6

Gestation days
Postnatal weeks
Postnatal years
Postnatal years

Abbreviations: GD, gestation day; PND, postnatal day.

0.0
0

7

14

21

28

35

42

49

56

63

70

Table 7. Estimated lengths of various life stages in humans inferred from the ages of sexual maturity in
mice, rats, and humans, and patterns of growth of body weight for rodents through 60 days of age, and for
humans through 16 years of age.

PND

Figure 9. Postnatal growth of ICR/Jcl mice, based
on data from Nomura (1976). Abbreviations: BW,
body weight; PND, postnatal day.
Table 4. Species differences in times of beginning
sexual maturity.
Species (time unit)
Mouse (months)
Rat (months)
Human (years)

Male

Female

1.5
1.8–2.1
11.5

1.0
1.8–2.1
10.5

Data from Kilborn et al. (2002).
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Rodent sex and life-stage equivalent
Males
GD12 to birth (fetal)
Birth to weaning
Weaning to 60 days
Females
GD12 to birth (fetal)
Birth to weaning
Weaning to 60 days

Mouse-based
estimate (days)

Rat-based
estimate (days)

Geometric
mean (days)

Geometric
SD

150
1,180
3,510

134
235
4,130

142
527
3,810

1.11
3.94
1.15

175
2,690
2,830

142
392
3,560

157
1,030
3,170

1.20
5.12
1.22

GD, gestation day. All data for this table were rounded to three significant figures. This overstates the likely accuracy of the
underlying projections. However, three significant figures are retained here to allow reasonably accurate reproduction of
our later calculations by other analysts.
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Table 8. Detailed results by life stage and sex: uncertainty distributions of risks for full lifetime exposures
to a generic mutagenic carcinogen at a constant dose rate per kilogram body weight3/4.
Percentile of uncertainty distribution
Males
1
2.5
5
10
25
50
75
90
95
97.5
99
Arithmetic mean
Females
1
2.5
5
10
25
50
75
90
95
97.5
99
Arithmetic mean

Fetal

Risk relative to adult period
Birth to weaning

Weaning to 60-day

0.011
0.018
0.026
0.039
0.078
0.173
0.392
0.764
1.20
1.72
2.89
0.351

0.054
0.084
0.135
0.220
0.565
1.44
3.77
7.79
10.7
13.2
17.4
2.92

0.167
0.217
0.273
0.365
0.563
0.882
1.38
2.03
2.53
3.18
3.91
1.09

0.000
0.000
0.001
0.001
0.004
0.014
0.047
0.137
0.278
0.505
0.961
0.072

0.004
0.007
0.012
0.023
0.069
0.210
0.564
1.09
1.57
2.10
2.79
0.432

0.012
0.021
0.034
0.049
0.074
0.107
0.150
0.199
0.233
0.273
0.323
0.118

The numbers represent the increment to lifetime relative risk/dose where the risk from treatment for the full adult period
is defined as 1.

Table 9. Overall results for constant mg/kg body weight3/4 dosing: uncertainty distributions of full lifetime
risks for lifetime exposures to a generic mutagenic carcinogen at a constant dose rate per kilogram body
weight3/4.
Percentile of uncertainty distribution

Male

1
2.5
5
10
25
50
75
90
95
97.5
99
Arithmetic mean

1.71
1.87
2.04
2.28
2.91
4.10
6.51
10.2
13.0
15.9
19.5
5.38

Full lifetime risk relative to adult period only
Female
Male and female population
1.19
1.20
1.22
1.25
1.31
1.46
1.78
2.33
2.77
3.33
4.06
1.66

1.45
1.53
1.63
1.76
2.11
2.78
4.15
6.26
7.89
9.62
11.8
3.52

Table 10. Overall results for constant mg/kg body weight1 exposures: uncertainty distributions of full lifetime incremental risks for lifetime exposures to a generic mutagenic carcinogen at a constant dose rate
per kilogram body weight1.
Percentile of uncertainty distribution

Male

1
2.5
5
10
25
50
75
90
95
97.5
99
Arithmetic mean

1.53
1.65
1.76
1.92
2.34
3.19
4.85
7.54
9.69
11.7
14.5
4.10
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Full lifetime risk relative to adult period only
Female
Male and female population
1.15
1.16
1.18
1.19
1.24
1.34
1.58
1.98
2.34
2.72
3.43
1.50

1.34
1.41
1.47
1.56
1.79
2.27
3.22
4.76
6.02
7.19
8.98
2.80
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In each case the numbers represent the increment to lifetime relative risk/dose where the
risk from treatment for the full adult period is
defined as 1. For example, the 50th percentile
of the uncertainty distribution under the “male
fetal” column is 0.173. This means that treatment at the similar dose rate to the mother
through the fetal period (rodent gestation day
12 equivalent through birth) is expected to
produce about 17% of the lifetime risk of
exposure to the generic mutagenic carcinogen
through the entire period of adulthood.
The potential aggregate public health significance of these results can be seen in the
“bottom line” distributions provided in Table 9.
The final column, aggregating results for males
and females, suggests that full lifetime risks for
full life constant exposure per kilogram of body
weight3/4 to a generic mutagenic carcinogen
are expected to be about 3.5 times larger than
would be estimated for similar exposure only
through the full period of adulthood. There is
appreciable uncertainty in this estimate (with
5–95% confidence limits corresponding to a
range from a 60% increment to nearly an
8-fold increment from adult-only exposure),
but it gives analysts and decision makers a starting point for reasoning about the potential risks
from early-life exposures to particular agents.
The milligram per kilogram body weight3/4
scenario quantified in Table 9 represents a reasonable generic case for exposure via an environmental medium (e.g., air) whose intake
depends on metabolism rates, which scale
approximately with the three-quarters power of
body weight. However, because many current
risk assessments are done based on dosages
expressed in milligrams per kilogram, rather
than milligrams per kilogram body weight3/4,
Table 10 and Figure 10 show comparable
results for a scenario in which there is constant
lifetime exposure in terms of simple milligrams
Lifetime risk increment/(mg/kg daily dose) relative
to average risk increment/daily dose during adulthood

Children’s Health

Est risk/(mg/kg dose) relative adult
U.S. EPA proposed risk/dose relative adult

16
14
12
10
8
6
4

2 U.S. EPA proposed risk assessment assumptions
Defined adult lifetime risk per daily mg/kg dose

0
0

2

4

6

8

10

12

14

16

Age (years)

Figure 10. Summary of mean model predictions for
the lifetime risk increment/(mg/kg dose-day) from
constant mg/kg-day exposures of children of various
ages (squares) compared with the U.S. EPA’s proposed assumptions (U.S. EPA 2003). Est, estimated.

113 | NUMBER 4 | April 2005 • Environmental Health Perspectives

Children’s Health

per kilogram body weight1. This scenario also
allows a direct comparison with expectations
under the U.S. EPA proposal (EPA 2003) of
factors of 10 and 3 for relative susceptibility
per milligrams per kilogram dose for the first
2 years, and ages 2–15, respectively. Overall,
Monte Carlo simulations using the constant
milligrams per kilogram dosing produce a mean
expected value for the lifetime risk that is
2.8 times what would be expected for adultonly exposure (compared with the 1.6 expected
under the U.S. EPA proposal; U.S. EPA 2003)
with 5–95% confidence limits of about
1.5–6 times the adult-only exposure risk. For
the U.S. EPA’s 0- to 2-year and 2- to 15-year
age groups (EPA 2003), we find mean expected
risk increments of 13.7- and 4.7-fold relative
to mean adult exposure risks, respectively.
These are in the range of 35–55% larger than
expected using the U.S. EPA’s proposed
10- and 3-fold factors (EPA 2003). Overall,
these are not large differences, considering the
relatively informal nature of the analysis underlying the U.S. EPA proposal; however, these
results suggest that further studies may well
suggest somewhat larger adjustments.
Both Tables 9 and 10 give results for each
sex separately for completeness. However, to
the degree that the sex-dependent differences
in age-related susceptibility depend on sexual
dimorphisms in CYP enzyme expression,
readers should be cautioned that some CYP
enzymes known to be expressed in a sexrelated fashion in rats do not appear to correspond to CYP enzymes that are known to be
present in humans (Mugford and Kedderis
1998). In the absence of direct human evidence that there are sex-related differences in
age-specific susceptibility as substantial as
those indicated in Tables 9 and 10, we recommend that risk assessors give most emphasis to the total population projections (both
sexes combined) in evaluating the potential
significance of early-life exposures.
There is one other “bottom line” inference that should be made clear. The results in
Tables 9 and 10 directly imply that it is more
likely than not that most of the total lifetime
risk of cancers from continuous milligrams
per kilogram-day or milligrams per kilogram3/4-day exposures to mutagenic carcinogens arises from exposures that are received
before adulthood.

Brief Discussion of Further
Needs for Risk and Uncertainty
Modeling to Estimate Full Life
Mutagenic Cancer Risks for a
Generic Example Chemical
Full application of these results to a real example chemical would ideally involve several
additional steps: a) quantification of any differential exposure of children of various life
Environmental Health Perspectives

stages relative to adults; b) integration of information from all available animal bioassays
deemed acceptable for human risk projections;
c) adjustments, if needed, for the inclusion of
a portion of the “weaning to 60-day” period in
the bioassays for the chemical, if the bioassays
began exposures before our assumed 60-day
starting point; d) integration of likelihoodbased uncertainties in estimated dose–response
slopes from the bioassay data into the overall
uncertainty analysis; and e) incorporation of
estimates of delivered dose, across species and
life stages, preferably with the aid of physiologically based pharmacokinetic models, along
with pharmacodynamic uncertainties in interspecies projections.
For example, data for induction of breast
cancers by dimethylbenz[a]anthracene clearly
indicate greater sensitivity in adolescent animals than either earlier or later in life (56%
tumor incidence in 6–8 week animals, compared with 8% for females < 2 weeks of age
and 15% for 26-week animals) (Ginsberg
2003; Meranze et al. 1969). [These specific
data were not separately broken out by the
U.S. EPA (2003) in its primary listing of
data, and thus were included only in the form
of a “total tumors” category in our original
analysis (Hattis et al. 2004).] The observed
age-dependent pattern of tumor induction
in the breast is probably related to the cell
division pattern in terminal end buds in the
development of that tissue (Russo and Russo
1999). Human data for this parameter (Russo
et al. 1987) might allow a greatly improved
rodent-to-human equivalent age mapping for
this tumor type.

Conclusions
Improved life-stage–specific analyses are possible based on current information. These
involve appreciable uncertainties, particularly
in the mapping of rodent exposure periods to
human equivalents. However, current understanding can at least provide decision makers
and the public with preliminary estimates of
the potential importance of exposures at early
life stages in the overall context of cancer risks
from genetically active agents. The suggestion
of the present analysis is that early-life exposure could make important contributions to
full-life cancer risks.
However, we offer the caveat that, because
of the multistage and multifactor nature of
cancer development, these analyses should be
grounded on the mode of action of the specific agent or classes of agents with putatively
similar modes of action. Specific agents affecting tumors at particular sites may also have
different age patterns of sensitivity than the
general run of mutagenic carcinogens represented in the present analysis. The present
results are based on early-life sensitivity data
for only nine chemicals, of which only five
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were classified as mutagenic. The conclusions
about early-life sensitivity for carcinogens with
different sites or modes of action could be
altered as data become available for bioassays
testing age-related differences in tumor risks
after exposures to a broader set of chemicals.
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